Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 26 2024 - 4:01PM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to advancing neurogenetic medicines, has entered into an
employment agreement with Toby Ferguson, M.D., Ph.D. that, among
other things, provides for the grant to Dr. Ferguson of a
non-qualified stock option and restricted stock units as an
inducement material to Dr. Ferguson’s entering into employment with
Voyager. The inducement awards were approved by the Compensation
Committee of Voyager’s Board of Directors in accordance with Nasdaq
Stock Market Listing Rule 5635(c)(4). The option award became
effective on March 25, 2024, and the restricted stock unit award is
scheduled to become effective on April 1, 2024.
The stock option award to Dr. Ferguson provides for the purchase
of an aggregate of 210,000 shares of Voyager’s common stock, and
the restricted stock unit award to Dr. Ferguson will represent
105,000 shares of Voyager’s common stock. The stock option has a
ten-year term and an exercise price of $9.26 per share, which is
equal to the closing price of Voyager's common stock on March 25,
2024, the effective date of grant. The stock option vests over four
years, with 25% of the shares underlying the stock option vesting
on the first anniversary of the effective date of grant and 75% of
the shares underlying the stock option vesting in 36 equal monthly
installments following the first anniversary of the effective date
of grant. The restricted stock unit award vests annually in equal
installments over three years, beginning on the first anniversary
of the effective date of grant. Vesting of Dr. Ferguson’s equity
awards is subject to Dr. Ferguson’s continued employment with
Voyager. Each equity award is also subject to the terms and
conditions of an award agreement.
About Voyager TherapeuticsVoyager Therapeutics,
Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to
leveraging the power of human genetics to modify the course of –
and ultimately cure – neurological diseases. Our pipeline includes
programs for Alzheimer’s disease, amyotrophic lateral sclerosis
(ALS), Parkinson’s disease, and multiple other diseases of the
central nervous system. Many of our programs are derived from our
TRACER™ AAV capsid discovery platform, which we have used to
generate novel capsids and identify associated receptors to
potentially enable high brain penetration with genetic medicines
following intravenous dosing. Some of our programs are wholly
owned, and some are advancing with partners including Alexion,
AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine
Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more
information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
ContactsTrista Morrison, NACD.DC,
tmorrison@vygr.com Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2024 to May 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From May 2023 to May 2024